Examkin

Question

Difficulty: HardGastroenterology and Hepatology

During morning rounds, the internal medicine team evaluates a 58-year-old man who was admitted three days ago for management of tense ascites. He has a known history of alcohol-associated cirrhosis. On admission, he underwent a 7-liter therapeutic paracentesis.

Current vital signs include a blood pressure of 96/60 mm Hg, heart rate of 92/min, and temperature of 36.9°C (98.4°F).

Over the past 24 hours, his urine output has decreased to 320 mL. Laboratory studies show a progressive rise in serum creatinine from 1.1 mg/dL on admission to 2.8 mg/dL today. Blood urea nitrogen is 48 mg/dL. Urinalysis reveals no red blood cells, white blood cells, or cellular casts. The spot urinary sodium concentration is <10< 10 mEq/L.

Following these results, diuretic therapy was discontinued, and the patient received a 48-hour volume expansion challenge with intravenous albumin. However, a repeat serum creatinine this morning remains elevated at 2.9 mg/dL. A renal ultrasound demonstrates normal kidney size with no evidence of hydronephrosis.

Which of the following is the most appropriate next step in the pharmacologic management of this patient's acute kidney injury?

  1. A
    Administration of intravenous furosemide
  2. B
    Initiation of empiric piperacillin-tazobactam
  3. C
    Placement of bilateral percutaneous nephrostomy tubes
  4. Initiation of midodrine and octreotide therapyAnswer
  5. E
    Referral for transjugular intrahepatic portosystemic shunt creation

Answer

Initiation of midodrine and octreotide therapy
The correct intervention is the administration of splanchnic vasoconstrictors (midodrine and octreotide). This patient meets the classic diagnostic criteria for Hepatorenal Syndrome (HRS) Type 1: advanced cirrhosis with ascites, acute kidney injury (creatinine > 1.5 mg/dL), no improvement in serum creatinine after at least 48 hours of diuretic withdrawal and volume expansion with albumin, absence of shock, and normal renal imaging. The underlying pathophysiology involves severe splanchnic vasodilation caused by portal hypertension, leading to decreased effective arterial blood volume and subsequent intense compensatory renal vasoconstriction. Midodrine (a systemic alpha-1 agonist) and octreotide (which inhibits the release of splanchnic vasodilators) work synergistically to reverse the splanchnic vasodilation, thereby restoring effective circulating volume and improving renal blood flow.

Step-by-Step Solution

1
Analyze the patient's presentation and laboratory findings.
A cirrhotic patient with ascites develops oliguria, a sharp rise in creatinine (1.1 to 2.8 mg/dL), and a very low urinary sodium (<10< 10 mEq/L) without hematuria or cellular casts.
These findings establish a diagnosis of acute kidney injury driven by pre-renal physiology (hypoperfusion), ruling out intrinsic renal damage like acute tubular necrosis.
2
Evaluate the response to diagnostic therapeutic interventions.
The creatinine remains elevated despite 48 hours of diuretic withdrawal and aggressive volume expansion with albumin. Ultrasound confirms no obstruction.
Lack of response to volume expansion confirms Hepatorenal Syndrome (HRS) rather than simple hypovolemia. Normal ultrasound definitively rules out post-renal obstruction.
3
Determine the appropriate first-line pharmacologic treatment for Hepatorenal Syndrome.
Splanchnic vasoconstrictors combined with albumin therapy.
Midodrine (a systemic alpha-1 agonist) and octreotide (a somatostatin analog) counteract the profound splanchnic vasodilation that drives HRS, successfully restoring effective circulating volume and renal perfusion.

Key Concept

Hepatorenal syndrome is a functional acute kidney injury in advanced cirrhosis characterized by extreme splanchnic vasodilation. Diagnosis requires a lack of response to volume expansion with albumin, and first-line medical treatment involves splanchnic vasoconstrictors (e.g., midodrine and octreotide or terlipressin).
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic